Syracuse University at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Syracuse University brings 3 presentations to ObesityWeek 2026 in National Harbor. Its program centers on new drug candidates, including a long-acting GLP-1 and Y2 receptor dual agonist and DG-260, a gliotransmitter analog for obesity and type 2 diabetes. It also compares metabolic adaptations after high-intensity interval training and time-restricted eating in young adults.

OrganizationObesityWeek 2026 Attendance
Universities & research institutes
Private research university in Syracuse, New York.
Talk
Sat Nov 14
10:45am–11:00am
Translating the Gliotransmitter Octadecaneuropeptide Analog, DG-260, Into a Obesity/T2DM Therapeutic
Metabolism and Integrative Physiology · Neuroscience · Pharmacology · Chronic Disease · Nutrition · Bariatric Surgery and Devices
Poster
Sat Nov 14
7:30pm–8:30pm

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Syracuse University

Tell us what you sell and we’ll find the people at Syracuse University most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction